Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 3 2Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Melanoma 1

Interventions

pembrolizumab 8Nivolumab 7Magnetic Resonance Spectroscopy 7Radiotherapy 6Biopsy 4Temozolomide 3Specimen Handling 3Irinotecan 3Ipilimumab 3Fluorodeoxyglucose F18 3Dexamethasone 3Bevacizumab 3venetoclax 2niraparib 2gallium 68 PSMA-11 2durvalumab 2avelumab 2Tobacco Use Cessation Devices 2Standard of Care 2Rituximab 2Positron-Emission Tomography 2Positron Emission Tomography Computed Tomography 2Paclitaxel 2Neoadjuvant Therapy 2Metastasectomy 2Immunoglobulin G 2FAPI-46 2Disulfides 2Cyclophosphamide 2Cetuximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Active not recruiting × binimetinib × Clear all
NCT03543969 2026-02-05

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Active not recruiting
14 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡